Bank of America Securities Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)

Business Insider

15-05-2025

Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report) yesterday and set a price target of $18.00. The company's shares closed yesterday at $17.16.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, PTC Therapeutics, and Alnylam Pharma. According to TipRanks, Ahmad has an average return of -5.3% and a 43.00% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $25.44 average price target, which is a 48.25% upside from current levels. In a report released on May 8, Stifel Nicolaus also maintained a Hold rating on the stock with a $18.00 price target.
Based on ACADIA Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $244.32 million and a net profit of $18.99 million. In comparison, last year the company earned a revenue of $205.83 million and had a net profit of $16.56 million
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year. Most recently, in March 2025, ELIZABETH A. GAROFALO, a Director at ACAD sold 4,919.00 shares for a total of $89,673.37.